Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Ltd has applied to the ASX for quotation of an additional 87,546 ordinary fully paid shares, issued in two tranches on March 6 and March 13, 2026. The new securities stem from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s share base and indicating continued utilisation of equity-based incentives or financing structures.
This incremental issuance may slightly dilute existing holdings but underscores ongoing engagement with capital markets to support corporate objectives. While small in scale, such routine share quotations help maintain liquidity in 4DMedical’s stock and can signal progress in employee or investor option programs that align stakeholders with the company’s long-term growth.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd is an ASX-listed company in the medical technology sector, trading under the code 4DX. The company issues ordinary fully paid shares, reflecting its capital market activities as it develops and commercialises its healthcare-related technologies and services.
Average Trading Volume: 7,109,493
Technical Sentiment Signal: Buy
Current Market Cap: A$2.51B
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.